Nabriva Therapeutics plc announced the appointment of Jennifer Schranz, M.D., as Chief Medical Officer. Dr. Schranz joins Nabriva Therapeutics from Shire plc, with nearly two decades of experience in clinical development and medical affairs. She joins the company in advance of the availability of topline results of its second Phase 3 global clinical trial for lefamulin which are expected in the Spring of 2018. In her role at Nabriva, Dr. Schranz will lead clinical development and medical affairs and contribute to the company’s business development strategy. Dr. Schranz held positions of increasing responsibility at Shire plc and at ViroPharma, most recently serving as the rare disease global development team lead where she oversaw clinical development, regulatory and life cycle management activities for the company’s hereditary angioedema franchise.